These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 24103756)

  • 1. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
    Ahrén B; Foley JE
    Int J Clin Pract Suppl; 2008 Mar; (159):8-14. PubMed ID: 18269436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
    Panina G
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():32-9. PubMed ID: 17877545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
    Del Prato S
    Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
    Azuma K; Rádiková Z; Mancino J; Toledo FG; Thomas E; Kangani C; Dalla Man C; Cobelli C; Holst JJ; Deacon CF; He Y; Ligueros-Saylan M; Serra D; Foley JE; Kelley DE
    J Clin Endocrinol Metab; 2008 Feb; 93(2):459-64. PubMed ID: 18042650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
    Roy S; Khanna V; Mittra S; Dhar A; Singh S; Mahajan DC; Priyadarsiny P; Davis JA; Sattigeri J; Saini KS; Bansal VS
    Life Sci; 2007 Jun; 81(1):72-9. PubMed ID: 17532347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The scientific evidence: vildagliptin and the benefits of islet enhancement.
    Mathieu C
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():9-17. PubMed ID: 19385979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
    Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of vildagliptin in the management of type 2 diabetes mellitus.
    Kleppinger EL; Helms K
    Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
    D'Alessio DA; Denney AM; Hermiller LM; Prigeon RL; Martin JM; Tharp WG; Saylan ML; He Y; Dunning BE; Foley JE; Pratley RE
    J Clin Endocrinol Metab; 2009 Jan; 94(1):81-8. PubMed ID: 18957505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
    Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
    Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
    Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
    Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
    Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
    Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
    Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
    Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice.
    Wu YJ; Guo X; Li CJ; Li DQ; Zhang J; Yang Y; Kong Y; Guo H; Liu DM; Chen LM
    Metabolism; 2015 Feb; 64(2):226-35. PubMed ID: 25195070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
    Akarte AS; Srinivasan BP; Gandhi S
    J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.